Chemo-Free Bladder Cancer Combo Wins Broader FDA Approval With Strong Survival Data
The FDA expanded approval of Keytruda plus Padcev for muscle-invasive bladder cancer, showing a 35% reduced death risk over standard chemotherapy.
Summary
The FDA has expanded approval of a chemotherapy-free combination — pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) — for adults with muscle-invasive bladder cancer (MIBC), now covering all eligible patients regardless of whether they can tolerate cisplatin. The approval is based on a large randomized trial of 808 patients showing the combo significantly outperformed standard gemcitabine-cisplatin chemotherapy. Patients on the new regimen had a 47% lower risk of disease progression or recurrence and a 35% reduced risk of death. Two-year survival rates reached 89.6% versus 81.3% for chemotherapy. The treatment is given both before and after surgery, targeting the tumor at multiple stages. This marks a meaningful shift toward immunotherapy-based, chemo-free treatment as a potential new standard of care for bladder cancer.
Detailed Summary
Muscle-invasive bladder cancer is an aggressive disease where the cancer has grown into the muscle wall of the bladder, typically requiring surgery and systemic therapy. Until now, platinum-based chemotherapy has been a cornerstone of perioperative treatment — given both before and after bladder removal surgery. This FDA approval signals a meaningful shift toward a chemo-free immunotherapy approach.
The FDA expanded approval of pembrolizumab combined with enfortumab vedotin for all adults with MIBC who are candidates for cystectomy — bladder removal surgery — regardless of their eligibility for cisplatin. Previously, this combination was only approved for cisplatin-ineligible patients. The expansion is based on data from the KEYNOTE-B15/EV-304 trial, a randomized, open-label study involving 808 previously untreated MIBC patients.
The trial results were striking. Median event-free survival was not reached in the new combination group, compared to 48.5 months with gemcitabine-cisplatin chemotherapy — a 47% reduction in the risk of progression or recurrence. At two years, 79.4% of patients on the combination remained event-free versus 66.2% on chemotherapy. Overall survival also favored the new regimen, with a 35% reduced risk of death and two-year survival rates of 89.6% versus 81.3%.
Experts highlight the perioperative design as critical — treating both before surgery to shrink tumors and after to eliminate residual cancer cells. Duke Cancer Institute's Dr. Christopher Hoimes called this a potential new standard of care for MIBC adults.
Caveats remain. The safety profile includes immune-related adverse reactions, peripheral neuropathy, skin reactions, and hyperglycemia. Long-term survival follow-up is still maturing since median overall survival was not yet reached in either group. Patients and clinicians should weigh efficacy gains against the distinct toxicity profiles of these newer agents compared to traditional chemotherapy.
Key Findings
- Keytruda plus Padcev reduced risk of disease recurrence or progression by 47% versus gemcitabine-cisplatin chemotherapy.
- Two-year overall survival reached 89.6% with the chemo-free combo versus 81.3% with standard chemotherapy.
- FDA approval now covers all MIBC adults eligible for cystectomy, not just those unable to tolerate cisplatin.
- The regimen is administered in both neoadjuvant and adjuvant phases, targeting cancer before and after surgery.
- Key side effects include immune-mediated reactions, peripheral neuropathy, skin reactions, and hyperglycemia.
Methodology
This is a regulatory news report from MedPage Today summarizing an FDA approval based on the Phase 3 KEYNOTE-B15/EV-304 randomized controlled trial. The trial enrolled 808 patients and is a credible, multicenter, open-label RCT. Evidence quality is high for an oncology intervention study.
Study Limitations
Median overall survival had not been reached in either arm at time of reporting, so long-term survival differences remain to be confirmed. The open-label trial design may introduce bias. Readers should consult the full prescribing information and primary trial publication for complete safety and subgroup data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: